Robotic Surgery on One Side of the Prostate for Early Prostate Cancer
Tests robotic surgery on one side of the prostate in men with early prostate cancer.
Plain-language title generated from the registry record
Registry title: Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer
Key facts
- Where
- Candiolo, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer on one side of the prostate only, with low or intermediate risk. The cancer must be limited to the prostate. They would have robot-assisted surgery on one half of the prostate.
- Age
- 40 years or older
- Sex
- Men only
- Disease stage
- Prostate cancer (acinar type) on one side only, limited to the prostate on MRI or PET-PSMA, with ISUP grade below 3. No spread to lymph nodes, bone or organs. PSA below 20 ng/mL. ECOG performance status 0-1.
- Earlier treatment
- No previous prostate surgery (TURP, adenomectomy). No other cancer drugs at the same time, including investigational hormone therapies.
- Biomarker or test result
- PSA below 20 ng/mL.
Main reasons for not taking part
- Special (rare) types of prostate cancer
- PSA above 20 ng/ml at diagnosis
- Cannot have an MRI (for example pacemaker, claustrophobia) or a PET-PSMA scan
- Serious illness or uncontrolled medical condition, including active infections
- Dementia or psychiatric illness that limits following the study or signing consent
Read by machine on 12 November 2026.
Where in Italy
- Fondazione del Piemonte per l'OncologiaCandiolo, ItalyContact: Enrico CheccucciTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fondazione del Piemonte per l'Oncologia
- Trial code
- NCT05832736
- Record updated
- 26 September 2023
- Original description
On the basis of the now consolidated literature and clinical experience of focal therapies, the execution of partial prostatectomy/hemiprostatectomy with robot-assisted laparoscopic technique can be proposed in a well-selected cohort of patients.Read full original descriptionShow less
Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer: a Prospective Idea, Development, Exploration, Assessment and Long-term Follow-up (I.D.E.A.L.) Trial
On the basis of the now consolidated literature and clinical experience of focal therapies, the execution of partial prostatectomy/hemiprostatectomy with robot-assisted laparoscopic technique can be proposed in a well-selected cohort of patients.
The hypothesis is that with this technique it is possible to achieve excellent levels of disease control, in terms of positive surgical margins (PSM) and biochemical recurrence of the disease (BCR), against a minimal impact as regards postoperative functional outcomes (continence and sexual power).
Inclusion: Signature of the informed consent and consent to the use of personal data; Prostate Specific Antigen (PSA) < 20 ng/mL; Unilateral organ-confined disease on MRI (performed according to ESUR recommendations and reported according to PiRads V.2) or PET-PSMA (performed according to the recommendations of the EANM and reported according to "EANM standardized reporting guidelines v1.0 for PSMA-PET"); Histological diagnosis of acinar-type prostate cancer unilateral on target biopsy and/or standard biopsy with ISUP < 3 and ipsilateral on imaging investigations; Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1; Life expectancy ≥ 5 years; Availability of the patient's pre-operative clinical data; Patients must be available to carry out the follow-up visits defined by the protocol; Absence of retroperitoneal, lymph nodal, bone or visceral metastatic lesions; Patients eligible for robot-assisted radical prostatectomy.
Exclusion: Previous prostate surgery (TURP, adenomectomy); Concomitant treatment with other antineoplastic drugs including investigational endocrine therapies; Special histotypes of prostate cancer; Serious underlying disease or uncontrolled medical condition including active and uncontrolled infections; Patients with dementia or psychiatric illness that limit compliance with study requirements or that could prevent understanding and/or signing the informed consent; Patients with PSA > 20 ng/ml at diagnosis; Impossibility to perform MRI (with pacemakers, claustrophobia…) or PET-PSMA.